amgen

By and large, short interest among the leading biotechs and emerging pharmaceuticals dwindled between the January 15 and January 30 settlement dates. Leading that trend were Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Here...

Biotechs continue to prove volatile this year. While Gilead Sciences, Inc. (NASDAQ: GILD) and Illumina, Inc. (NASDAQ: ILMN) saw a sizable drops in short interest between the September 15 and September 30 settlement dates, short sellers loaded up on Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX...

U.S. stocks were mixed as the Fed continued to wind down its monthly asset purchase program by another $10 billion. The Fed noted that the economy rebounded in the second quarter despite significant under-utilization remaining in the labor market. As such, the Fed noted, it will maintain a...

Cowen analysts recently released a research report that focused on biotech stocks with promising Phase 3 data leading into the U.S. Food and Drug Administration (FDA) approval process. ACADIA Pharmaceuticals (NASDAQ: ACAD), Alexion Pharmaceuticals (NASDAQ: ALXN), InterMune (NASDAQ: ITMN) and...

This weekend in Barron's online: an exclusive ranking of the best annuities, alternatives to junk bonds, as well as the prospects for Apache, Pier 1 Imports and more. Cover Story "Top 50 Annuities" by Karen Hube. Investors planning for retirement want simple products with low...

While Amgen (NASDAQ: AMGN) saw a sizable dip in short interest between the April 30 and May 15 settlement dates, short sellers piled on Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC). Among other leading biotechs and emerging pharmaceuticals, gains in the number of their shares sold...

Biotech stocks have proved to be volatile this year, and short sellers piled on Incyte (NASDAQ: INCY) between the April 15 and April 30 settlement dates. Pharmacyclics (NASDAQ: PCYC) and Regeneron Pharmaceuticals (NASDAQ: REGN) also saw double-digit percentage increases in the number of their...

U.S. stocks fell after the S&P 500 and Nasdaq has risen for six consecutive trading sessions after new home sales data came in worse than expected. Investors could reasonably expect the markets to cool off after six straight days of gains especially as earnings continue to come in mixed....

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates. But Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) were among those that bucked the...

U.S. stocks were slightly lower as positive labor market data clashed with fourth quarter GDP estimates that showed the economic expanded less than economists had expected. Major indices finished slightly lower as the Nasdaq index continues to see its losses fall sharper compared to the Dow and...

After largely shying away in the previous period, short sellers found renewed interest in many of the leading biotech and emerging pharmaceutical companies between the February 28 and March 14 settlement dates. But Celgene (NASDAQ: CELG), Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC...

U.S. stocks extended Monday's gains despite lingering concerns over Crimea. Russian President Vladimir Putin has authorized a draft treaty for Crimea to join Russia. U.S. economic data showed that housing starts in February remain healthy with modest gains. The Dow gained 0.55 percent,...

Short interest in most of the leading biotech and emerging pharmaceutical companies declined between the February 14 and February 28 settlement dates. But Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) bucked that trend. Short interest in Gilead...

Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...

Shares of the following exchange traded funds are trading more than 20 percent higher than 90 days ago, and they are within 10 percent of their 52-week highs. This set of ETFs provides a peek at areas of investor interest during and after the holiday shopping season, as uncertainty over the...